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Abstract
BACKGROUND—The HPTN 046 trial evaluated the efficacy of extended infant nevirapine
(NVP) administration for prevention of HIV transmission through breastfeeding. Infants received
daily NVP to 6 weeks of age. HIV-uninfected infants (the intent-to-treat group) received daily
NVP or placebo up to 6 months of age. We analyzed emergence of NVP resistance in infants who
acquired HIV-infection despite prophylaxis.
METHODS—HIV genotyping was performed using the ViroSeq HIV Genotyping System.
Medians and proportions were used to summarize data. Two-sided Fisher’s exact tests were used
to evaluate associations between categorical variables.
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RESULTS—NVP resistance was detected in 12 (92.3%) of 13 infants who were HIV-infected by
6 weeks and in seven (28%) of 25 infants who were HIV-uninfected at 6 weeks and HIV-infected
at 6 months of age (6/8=75% in the NVP arm, 1/17=5.9% in the placebo arm, P=0.001). Among
those 25 infants, 4 had mothers who initiated an antiretroviral (ARV) treatment regimen by 6
months postpartum. In all 4 cases, the treatment regimen included a non-nucleoside reverse
transcriptase inhibitor (NVP or efavirenz). NVP resistance was detected in all four of those infants
by 6 months of age (4/4=100%). In contrast, only three (14.2%) of the remaining 21 HIV-infected
infants whose mothers did not initiate ARV treatment developed NVP resistance (P=0.003).
CONCLUSIONS—Extended NVP prophylaxis significantly increased the risk of NVP resistance
in infants who acquired HIV infection after 6 weeks of age. Treatment of maternal HIV infection
was also associated with emergence of NVP resistance in HIV-infected, breastfed infants.
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The risk of mother-to-child transmission (MTCT) of HIV through breastfeeding can be
reduced by providing infants with daily infant nevirapine (NVP) prophylaxis [1–3] or by
providing the mother with a triple-drug regimen during the postpartum period, either for
prevention of MTCT of HIV (PMTCT), or as treatment for her own HIV infection [4–8].
Unfortunately, infants who are HIV-infected despite NVP prophylaxis often acquire NVP
resistance that may compromise their ability to respond to NVP-containing treatment
regimens [9–14]. NVP resistance often emerges in HIV-infected infants after exposure to
single dose NVP (sdNVP) or other short course regimens for PMTCT [15, 16]. Provision of
extended daily NVP to infants for PMTCT further increases the risk of NVP resistance in
the subset of infants who are HIV-infected despite prophylaxis. In the Six Week Extended-
Dose NVP (SWEN) trial [1], 21 (84.0%) of 25 HIV-infected Ugandan infants [10] and 11
(91.7%) of 12 HIV-infected Indian infants [11] who received up to 6 weeks of daily NVP
had NVP resistance at 6 weeks of age [1]. In the Post-Exposure Prophylaxis in Infants trial
in Malawi (PEPI-Malawi) [2], 44 (83.0%) of 53 HIV-infected infants who received up to 14
weeks of daily NVP had NVP resistance at 14 weeks of age [12]. In both the SWEN and
PEPI-Malawi trials, NVP resistance mutations were still detectable in most infants at 6
months of age [10–12, 17].
As ARV drugs become more widely available in resource-constrained settings for PMTCT
and for maternal and infant HIV treatment, analysis of ARV resistance in perinatal HIV
prevention trials becomes more complex. HIV-infected infants may acquire resistance as a
result of exposure to study drugs, but may also acquire resistance as a result of exposure to
ARV drugs administered to the mother or infant outside of the study for PMTCT or
treatment. Our previous studies demonstrated that breastfeeding infants who were HIV-
infected despite receiving ARV prophylaxis can acquire resistance to ARV drugs in their
mother’s treatment regimen. When women initiated highly active ARV treatment (HAART)
in the first year after delivery, six (85.7%) of seven HIV-infected infants in the SWEN trial
[18] and 11 (29.7%) of 37 HIV-infected infants in the PEPI-Malawi trial [13] acquired
multi-class ARV resistance (resistance to NVP, a non-nucleoside reverse transcriptase
inhibitor [NNRTI] plus resistance to nucleoside or nucleotide reverse transcriptase inhibitors
[NRTIs]). In those studies, it was not possible to determine whether the infant acquired
NNRTI resistance from the PMTCT regimen or from exposure to an NNRTI in the mother’s
treatment regimen. Therefore, it is important to consider all sources of ARV exposure when
evaluating drug resistance in infants who received an ARV regimen for PMTCT.
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HPTN 046 was a randomized, placebo-controlled clinical trial performed in South Africa,
Tanzania, Uganda, and Zimbabwe [3] that assessed the safety and efficacy of extending
daily infant NVP from 6 weeks to 6 months for prevention of postnatal HIV transmission. In
HPTN 046, most women received sdNVP at the time of delivery and most infants received
sdNVP with a short course of zidovudine (ZDV) shortly after birth, according to local
treatment guidelines at each site [3]. Some women also received ZDV and/or lamivudine
(3TC) for PMTCT. Between birth and one week of age, all infants initiated a 6-week course
of daily, open-label NVP. At 6 weeks of age, HIV-uninfected infants (intent-to-treat group)
were randomized to either receive daily NVP or placebo through six months of age or until
the cessation of breastfeeding, whichever was first. Study drug was stopped in infants with
confirmed HIV infection and those infants were referred for ARV treatment. Some women
in HPTN 046 initiated HAART outside of the study for their own health [3]. In this report,
we analyzed factors associated with emergence of ARV resistance in infants in the HPTN
046 trial who were HIV-infected despite extended daily NVP prophylaxis and were also
exposed to maternal ARV drugs for PMTCT or treatment.
MATERIALS AND METHODS
Samples used for analysis
Samples were obtained from HPTN 046 (NCT 00074412) version 3.0 [3]. Infants were
followed to 18 months of age and plasma was stored within 7 days of birth, at 2, 5, 6, and 8
weeks, and 3, 6, 9, 12 and 18 months. Infants were tested for HIV infection with an HIV-1
DNA PCR test up to and including 12 months of age. At 18 months, infants were tested for
HIV infection using an HIV enzyme immunoassay or HIV rapid test. This report includes
analysis of NVP resistance at 6 months for HIV-infected infants in the intent-to-treat group
(those who were HIV-uninfected at 6 weeks of age). NVP resistance was also analyzed at 6
weeks for infants who were HIV-infected by 6 weeks of age; this included infants who were
randomized in the trial at 6 weeks of age and subsequently diagnosed with HIV infection
that seemingly occurred between 6 weeks and 8 weeks, as well as infants who were not
randomized because they were diagnosed with HIV-infection by 6 weeks of age.
Longitudinal plasma and breast milk samples from women who started HAART by 6
months postpartum were also analyzed for ARV resistance.
HIV Genotyping
Infant plasma, maternal plasma, and breast milk samples were analyzed using the ViroSeq
HIV-1 Genotyping System v2.8 (Celera, Alameda, CA). Breast milk samples with HIV viral
loads >400 copies/ml were also analyzed. HIV genotyping was performed according to the
manufacturer’s instructions, with the following exceptions: infant samples were tested using
100 µl of plasma, and a nested PCR procedure [19] was used to amplify plasma and breast
milk samples that failed PCR amplification with standard test procedures. HIV sequences
were analyzed for the presence of mutations associated with resistance to NNRTIs, NRTIs,
and protease inhibitors (PIs). HIV subtypes were determined by phylogenetic analysis as
previously described [20] using PHYLIP v3.66.
Statistical Analysis
Medians and proportions were used to summarize the data. Two-sided Fisher’s exact tests
were used to test hypotheses about associations between categorical variables.
Ethical considerations
The study was approved by ethics review committees at each study site, and institutional
review boards of partner institutions in the United States, if applicable. Written informed
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consent for participation in the HPTN 046 trial was obtained from the infants’ parents or
legal guardians.
GenBank Accession Numbers
Sequences analyzed in this report were submitted to GenBank (accession numbers:
JQ730752-JQ730813).
RESULTS
Overview of the study cohort
One-thousand seven-hundred infants were enrolled in HPTN 046 and initiated a course of
daily open-label NVP (Figure 1). At six weeks of age, 1,527 breastfeeding infants were
randomized to receive either daily NVP prophylaxis (NVP arm) or placebo (placebo arm)
for up to six months of age or until the cessation of breastfeeding if stopped earlier than six
months. This included 1,522 infants who were HIV-uninfected at 6 weeks of age (intent-to
treat group, Figure 1) and five infants who were randomized before HIV infection was
diagnosed. The study regimen (NVP or placebo) was initiated in 1,519 infants, and HIV
infection status was known for 1,462 (96.2%) of those infants at 6 months of age (729 in the
NVP arm, 733 in the placebo arm). Twenty-six (1.8%) of the 1,462 infants who were
randomized acquired HIV infection by 6 months of age (8 in the NVP arm, 18 in the placebo
arm, Figure 1). In addition, nine (5.2%) of the 173 infants who were not randomized were
HIV-infected by 6 weeks of age (Figure 1).
ARV drug resistance was assessed in 38 infants. This included 25 of the 26 infants who
were HIV-uninfected at 6 weeks of age (Table 1) and 13 of the 14 infants who were HIV-
infected at 6 weeks of age (Supplemental Digital Content). The majority of women and their
infants studied received non-study ARV drugs for PMTCT according to the standard of care
in their country. Thirty-six (94.7%) of the 38 women received sdNVP in labor, and 26
(68.4%) of the 38 women received additional ARV prophylaxis; 17 (44.7%) received
zidovudine (ZDV, starting 1–137 days prior to delivery and ending near the time of
delivery) and nine (23.7%) received a combination of ZDV and 3TC (starting 0–66 days
prior to delivery and extending up to 11 days postpartum). All but one of the infants
received sdNVP, and 26 (68.4%) of the infants received a 1-week or 4-week regimen of
ZDV (Tables 1 and 3). In addition, eight (21.1%) of the women and seven (18.4%) of the
infants initiated HAART within the first 6 months after delivery (Tables 1 and 3). The
women and infants in this study, who started HAART by 6 months after birth initiated an
NNRTI-containing HAART regimen and a co-formulated lopinavir/ritonavir (LPV-r)-
containing HAART regimen, respectively.
Analysis of NVP resistance in infants who were HIV-infected between 6 weeks and 6
months of age
Eight infants in the NVP arm and 18 infants in the placebo arm who were HIV-uninfected at
6 weeks acquired HIV infection by 6 months of age (Figure 1); 25 (96.2%) of those infants
had a 6-month sample available for analysis (Table 1). The infants were diagnosed with HIV
infection at a median of 182 days of age (range 87–238 days). Infants in the NVP arm
received a median of 173 days (range 92–182 days) of NVP (open-label NVP plus NVP as
study drug). Infants in the placebo arm received a median of 37 days (range 26–38 days) of
open-label NVP. Six (75.0%) of the eight HIV-infected infants in the NVP arm had NVP
resistance, compared to only one (5.9%) of the 17 HIV-infected infants in the placebo arm
(P=0.001, Table 3).
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There was no association between emergence of NVP resistance in infants at 6 months of
age and any of the following factors: off-study NRTI exposure for PMTCT (maternal ZDV
prophylaxis, maternal 3TC prophylaxis, or infant ZDV prophylaxis) or initiation of infant
HAART by 6 months of age, timing of infant HIV infection (infection by 3 months of age),
or HIV subtype (C vs. other subtypes, Table 3). In contrast, emergence of NVP resistance in
infants at 6 months of age was associated with initiation of maternal HAART by 6 months
postpartum (P=0.003, Table 3). All infants whose mothers initiated an NNRTI-containing
regimen by 6 months postpartum had NVP resistance; three of the infants were in the NVP
arm (infants 2, 4, and 5) and one infant was in the placebo arm (infant 9). In the placebo
arm, the only infant who had NVP resistance had a mother who was receiving NNRTI-based
HAART. In the NVP arm, three (50%) of the six infants who had NVP resistance had a
mother who was receiving NNRTI-based HAART.
Analysis of NVP resistance in infants who were HIV-infected by 6 weeks of age
Fourteen of the infants studied were HIV-infected by 6 weeks of age; five were diagnosed
with HIV infection after randomization (3 in the NVP arm, 2 in the placebo arm) and nine
were not randomized to study drug (Figure 1). Thirteen (92.9%) of those infants had a 6-
week plasma sample available for analysis (Supplemental Digital Content). The median age
at HIV diagnosis was 36 days (range 14–85 days). Infants who were randomized to NVP or
placebo at 6 weeks of age received a median of 93 days (range: 37–97 days) of NVP (open-
label NVP with or without NVP as study drug). Infants who were not randomized received a
median of 35 days (range: 12–39 days) of daily NVP prophylaxis, begun at an average of 6
days after birth. NVP resistance was detected in 12 (92.3%) of the 13 infants who were
HIV-infected by 6 weeks of age (Supplemental Digital Content).
Analysis of resistance to other antiretroviral drugs
Many infants were exposed to ARV drugs other than NVP, including NRTI’s administered
to mothers and/or infants for PMTCT, and HAART administered to mothers and/or infants
for treatment of HIV infection. In four cases where resistance testing was performed at 6
months (infants 2, 4, 5 and 9), the mother initiated HAART before the 6-month visit while
she was still breastfeeding (Table 1). None of the 25 infants in the intent-to-treat group had
resistance to drugs other than NVP at 6 months of age (Table 1). Two infants in the intent-
to-treat group (infants 3 and 10) initiated HAART by 6 months; none of those infants had
ARV resistance detected at 6 months.
The mothers of two of the 13 infants who had resistance assessed at 6 weeks initiated
HAART before the 6-week visit while their infants were still breastfeeding (infants 26 and
27). Neither of those infants (and none of the other 11 infants infected by 6 weeks of age)
had resistance to drugs other than NVP at 6 weeks. Five of the 13 infants who were HIV-
infected by 6 weeks were not diagnosed by the 6-week visit and were randomized in the
HPTN 046 trial. All five of those infants initiated HAART by 6 months. Four of those five
infants had a sample collected at the 6-month visit. Three of the infants had ARV resistance
detected at 6 months of age; two infants had NVP resistance detected and one infant had
3TC resistance (M184V mutation) detected at 6 months of age (infant 30, Supplemental
Digital Content). That infant did not receive 3TC prophylaxis and the mother did not receive
3TC as prophylaxis or as part of HAART. However, the infant initiated a 3TC-containing
HAART regimen before the 6-month visit (at 156 days of age).
More detailed analysis was performed for the eight infants whose mothers started HAART
by 6 months postpartum (Table 2). All eight infants were exclusively breastfeeding when
their mothers started HAART. For these eight mother-infant pairs, HIV genotyping was
performed for all available maternal plasma, breast milk, and infant plasma samples
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collected after infant HIV infection up to 6 months postpartum (Table 2). Six of the eight
women had a genotyping result for at least one plasma sample; four of those women had
NVP resistance detected. Five of the eight women had a genotyping result for at least one
breast milk sample; three of those women had NVP resistance detected. Seven (88%) of the
eight infants had NVP resistance detected. In addition to NVP resistance, one of the eight
infants (infant 34) had the K65R mutation, associated with resistance to NRTIs, including
3TC and stavudine (d4T), detected at 3 months of age [21]. In this mother-infant pair,
neither mother nor infant received 3TC for PMTCT, and the infant did not receive HAART.
However, the mother started a regimen of 3TC, d4T, and NVP at 63 days postpartum, after
the infant was diagnosed with HIV infection while she was still breastfeeding. In this case,
exposure to 3TC and/or d4T in the mother’s HAART regimen was the likely explanation for
emergence of multi-class (NNRTI plus NRTI) resistance in the infant.
DISCUSSION
We analyzed ARV resistance in HIV-infected infants in the HPTN 046 trial. Among HIV-
infected infants who were HIV-uninfected at 6 weeks, the frequency of NVP resistance was
significantly higher in the NVP arm than in the placebo arm at 6 months (75% of the infants
had resistance in the NVP arm, compared to only 5.9% in the placebo arm). Notably, almost
all (92%) of the infants who were HIV-infected by 6 weeks and received extended daily
NVP prophylaxis had NVP resistance at 6 weeks of age. This is consistent with the high
frequency of NVP resistance observed at 6 and 14 weeks of age among infants in the SWEN
and PEPI-Malawi trials [10–12, 22].
In HPTN 046, many women and infants received ARV drugs for PMTCT or HIV treatment
(maternal or infant HAART) in addition to the study regimen. Emergence of NVP resistance
in infants at 6 months was not associated with exposure to ZDV or 3TC administered to the
mother or infant near the time of birth for PMTCT, to initiation of infant HAART, timing of
infant HIV infection (detected by vs. after 3 months), or HIV subtype (C vs. non-C). A
failure to see an association of NVP resistance with these factors may have been due to the
relatively small number of infants analyzed, particularly in some subgroups. In contrast,
emergence of NVP resistance at 6 months in the intent-to-treat group was associated with
initiation of maternal HAART including NVP or EFV before 6 months postpartum. In the
placebo arm, the only infant who had NVP resistance had a mother who was receiving
NNRTI-containing HAART. In the NVP arm three (50%) of six infants with NVP resistance
had mothers who had initiated NNRTI-containing HAART.
The increased risk of NVP resistance in infants whose mothers initiate NNRTI-containing
HAART postpartum may be due to NVP exposure through breast milk and/or transmission
of NVP-resistant HIV strains from the mother to the infant. When nursing mothers receive
NVP, NVP concentrations in breast milk are around 70% of those in maternal plasma, and
the infants receive a sufficient NVP dose via breast milk to achieve infant plasma NVP
concentrations of around 1000 ng/mL, well above the IC50 of 10 ng/mL. [23, 24].
Transmission of NVP-resistant HIV from a woman to her infant has been documented [10,
25]. In this study, NVP-resistant HIV was detected in breast milk in three of the five women
who had HIV genotyping results obtained for breast milk samples. In one case, it is possible
that a NVP-resistant strain was transmitted from the mother to her infant.
In this cohort, emergence of resistance to drugs other than NVP was uncommon. One infant
acquired the M184V mutation, most likely as a result of exposure to the infant’s own
HAART regimen. In addition, one of eight breastfeeding infants who were exposed to
maternal HAART acquired multi-class resistance: NVP resistance and the K65R mutation,
which is associated with resistance to NRTIs such as 3TC, d4T. In this case, acquisition of
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the K65R mutation was likely to have resulted from exposure to 3TC and/or d4T in the
mother’s HAART regimen. 3TC is concentrated in breast milk, with average concentrations
about 2.5 fold higher than in maternal plasma, and 3TC concentrations in the plasma of
breastfeeding infants average 20 ng/mL, just above the upper limit of the range of the 3TC
IC50 for wild-type HIV (0.6 to 21 ng/mL) [23, 25]. The K103N mutation was selected in the
infant prior to maternal HAART exposure. Other NVP resistance mutations were detected in
samples collected at later study visits; these NVP resistance mutations may have been
selected in the infant either from the infant’s NVP prophylaxis or from NVP exposure in the
mother’s HAART regimen. Acquisition of multi-class resistance in breastfeeding infants
exposed to maternal HAART was less frequent in this study (1/8 infants, 12.5%) than in
other studies [13, 14, 18]. This may reflect the relatively short period of time between
maternal HAART initiation and collection of the infant samples used for testing (maximum
3 months). In previous studies, infants were tested for resistance 6 months or more after
maternal HAART initiation [13, 18]. Another factor that may have contributed to the
relatively low frequency of multi-class resistance in infants in this study is that three (38%)
of the eight women studied initiated HAART more than 3 months after delivery. In the
PEPI-Malawi trial, emergence of multi-class resistance was more frequent in infants whose
mothers initiated HAART closer to the time of delivery [13].
This study extends findings from the SWEN trial [10, 11, 17] and the PEPI-Malawi trial [12,
22] by examining NVP resistance in infants who received up to 6 months of extended daily
NVP. This study also identifies an additional risk factor for acquisition of NVP resistance in
breastfeeding infants: initiation of maternal HAART by 6 months postpartum. The World
Health Organization (WHO) currently recommends more wide-spread use of HAART in
pregnant and breastfeeding women who meet the criteria for treatment [26]. The WHO also
recommends that women who start HAART within 12 months of sdNVP exposure start a
non-NNRTI-containing HAART regimen [26]. However, NVP is commonly included in
first-line regimens used to treat HIV-infected mothers and infants in these settings, despite
previous sdNVP exposure. HIV-infected infants who were exposed to NVP prophylaxis
prior to HIV diagnosis are not likely to respond to a NVP-containing treatment regimen
[27]. Resistance testing is not readily available in most resource-constrained settings.
Therefore, it is often not possible to screen infants for NVP resistance before starting an
ARV treatment regimen. Findings from this study support the current guidelines of the
WHO that HIV-infected infants should be treated with a regimen that does not include an
NNRTI if they were exposed to sdNVP, other NVP-containing regimens used for PMTCT,
or a maternal HAART regimen that included NVP or another NNRTI [28]. This study also
provides further evidence that initiation of maternal HAART can induce multi-class
resistance in breastfeeding infants who become HIV-infected. Infants who develop NRTI
resistance, in addition to NVP resistance, may not respond to any of the treatment regimens
that are available in resource-limited settings. Further studies are needed to evaluate factors
associated with emergence of multi-class resistance in HIV-infected infants.
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Refer to Web version on PubMed Central for supplementary material.
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HIV genotyping results obtained for maternal plasma, breast milk, and infant plasma
samples from eight mother-infant pairs where the mother started highly active antiretroviral
therapy (HAART) by 6 months postpartum; all available samples were tested. Samples were
collected at 6 weeks, and at 3 and 6 months postpartum. Shaded boxes indicate the study
visits the mother was on HAART. HIV genotyping was not performed for maternal samples
that had <400 copies/ml (c/ml) HIV RNA (VL<400c/ml). (a) A nested polymerase chain
reaction (PCR) procedure was required for amplification. (b) HIV genotyping results for this
infant did not include amino acids 8 to 32 in HIV reverse transcriptase. No major non-
nucleoside reverse transcriptase inhibitor (NNRTI) or nucleoside / nucleotide reverse
transcriptase inhibitor (NRTI) resistance mutations occur in that region of the reverse
transcriptase protein.
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Table 3
Factors associated with detection of NVP resistance in infants HIV-infected between 6 weeks and 6 months of
age.*
Factor N (%) Relative Risk
(95 %CI [IQR])
P-value
ARV exposure from study NVP arm 6/8 (75.0 %) 12.8 (1.8 – 89.0) 0.001
regimen Placebo arm 1/17 (5.9 %)
ARV exposure for PMTCT
Maternal ZDV prophylaxis:
0.5 (0.2 – 1.8) 0.355Yes 4/18 (22.2 %)
No 3/7 (42.9 %)
Maternal 3TC prophylaxis:
0.4 (0.1 – 2.9) 0.626Yes 1/7 (5.9 %)
No 6/18 (75.0 %)
Infant ZDV prophylaxis:
2.3 (0.3 – 16.1) 0.626Yes 6/18 (33.3 %)
No 1/7 (14.3 %)
ARV exposure for maternal or infant treatment
Maternal HAART by 6 months postpartum
7.0 (2.5 – 20.0) 0.003Yes 4/4 (100.0 %)
No 3/21 (14.2 %)
Infant HAART by 6 months of age
-- 1.000Yes 0/2 (0.0 %)
No 7/23 (30.4 %)
Other factors
HIV-infected by 3 months
0.4 (0.1 – 3.0) 0.626Yes 1/7 (14.3 %)
No 6/18 (75.0 %)
HIV subtype
1.9 (0.3 – 12.8) 0.637C 6/19 (31.6 %)
A 1/6 (16.7 %)
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